Regulation 213 Amendment of regulation 281 (duties of authorisation holders and registration holders)I1
United Kingdom
In regulation 281(1)—
(a)
in sub-paragraph (a), insert “ UK ” before “marketing authorisation”;
F1(b)
omit “or” at the end of sub-paragraph (c); and
(c)
in sub-paragraph (d), after “for a medicinal product” insert—
“; or
(e)an EU marketing authorisation for a medicinal product.”.
Annotations
Textual amendments
- F1
Reg. 213(b)(c) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 169
Commencement
- I1
Reg. 213 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1